AnaptysBio has reported that the ARISE-AD trial of its investigational B and T lymphocyte attenuator (BTLA) agonist, ANB032, ...

Phase IIb study on ANAB's ANB032 for atopic dermatitis fails to meet goals. The company decides to discontinue any further investment in the candidate.

Derek Archila, an analyst from Wells Fargo, assigned the Buy rating on AnaptysBio (ANAB – Research Report). The associated price target is ...

Shares of AnaptysBio Inc. remained flat in premarket trading Thursday after plunging over 32% in the prior session, marking ...

Fintel reports that on December 11, 2024, HC Wainwright & Co. downgraded their outlook for AnaptysBio (NasdaqGS:ANAB) from Buy to Neutral. Analyst Price Forecast Suggests 257.63% Upside As of December ...

Months Before C.E.O.’s Killing, the Suspect Went Silent. Where Was He? New details are emerging about Luigi Mangione’s growing impatience with “a capitalist society” and his search for ...

Columvi combo in DLBCL, while AnaptysBio's ANB032 fails in atopic dermatitis. Essential Pharma gets €1.2B financing deal.

Canada Post, union still at odds as strike nears 1 month Canada Post, union still at odds as strike nears 1 month Canada Post says the latest offer from the union representing its striking workers ...

Whether you’re a fan of the All Blacks, a follower of the women’s game or someone who watches every phase of play in the Premiership, our rugby features and news pieces will provide you with all of ...

Exclusive: peaq Launches DePIN Enterprise Adoption Program with Bosch, Lufthansa IH, Deutsche Telekom, Bertelsmann Investments, and TUM ...